Literature DB >> 33495225

In Vivo Antibacterial Activity of Acetazolamide.

Nader S Abutaleb1,2, Ahmed Elkashif1, Daniel P Flaherty3,4,5, Mohamed N Seleem6,2.   

Abstract

Vancomycin-resistant enterococci (VRE) represent a major public health threat that requires the development of new therapeutics. In the present study, acetazolamide (AZM) was evaluated against enterococci. It inhibited different enterococcal strains tested at clinically achievable concentrations. Moreover, AZM outperformed linezolid, the drug of choice for VRE infections, in two in vivo VRE mouse models-murine colonization-reduction and VRE septicemia. Collectively, these results indicate that AZM warrants consideration as a promising treatment option for VRE infections.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  VRE bloodstream infections; VRE decolonization; acetazolamide; carbonic anhydrase inhibitors; vancomycin-resistant enterococci (VRE)

Year:  2021        PMID： 33495225      PMCID： PMC8097480          DOI： 10.1128/AAC.01715-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Relationships between enterococcal virulence and antimicrobial resistance.

Authors:  L M Mundy; D F Sahm; M Gilmore
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans.

Authors:  Carles Ubeda; Ying Taur; Robert R Jenq; Michele J Equinda; Tammy Son; Miriam Samstein; Agnes Viale; Nicholas D Socci; Marcel R M van den Brink; Mini Kamboj; Eric G Pamer
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

3.  Pharmacokinetics and pharmacodynamics of acetazolamide in patients with transient intraocular pressure elevation.

Authors:  I Yano; A Takayama; M Takano; M Inatani; H Tanihara; Y Ogura; Y Honda; K Inui
Journal:  Eur J Clin Pharmacol       Date:  1998-03       Impact factor: 2.953

4.  Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M).

Authors:  S Fiedler; J K Bender; I Klare; S Halbedel; E Grohmann; U Szewzyk; G Werner
Journal:  J Antimicrob Chemother       Date:  2015-12-18       Impact factor: 5.790

5.  Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora.

Authors:  H Lode; N Von der Höh; S Ziege; K Borner; C E Nord
Journal:  Scand J Infect Dis       Date:  2001

6.  Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin.

Authors:  M T Wong; C A Kauffman; H C Standiford; P Linden; G Fort; H J Fuchs; S B Porter; R P Wenzel
Journal:  Clin Infect Dis       Date:  2001-10-04       Impact factor: 9.079

Review 7.  Clinical management of non-faecium non-faecalis vancomycin-resistant enterococci infection. Focus on Enterococcus gallinarum and Enterococcus casseliflavus/flavescens.

Authors:  Jacopo Monticelli; Anna Knezevich; Roberto Luzzati; Stefano Di Bella
Journal:  J Infect Chemother       Date:  2018-02-01       Impact factor: 2.211

8.  Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus.

Authors:  Jatinder Kaur; Xufeng Cao; Nader S Abutaleb; Ahmed Elkashif; Amanda L Graboski; Aaron D Krabill; Ahmed Hassan AbdelKhalek; Weiwei An; Atul Bhardwaj; Mohamed N Seleem; Daniel P Flaherty
Journal:  J Med Chem       Date:  2020-08-11       Impact factor: 7.446

9.  Cerebral vasoreactivity assessed with transcranial Doppler and regional cerebral blood flow measurements. Dose, serum concentration, and time course of the response to acetazolamide.

Authors:  A Dahl; D Russell; K Rootwelt; R Nyberg-Hansen; E Kerty
Journal:  Stroke       Date:  1995-12       Impact factor: 7.914

10.  Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.

Authors:  Martin W ten Hove; Deborah I Friedman; Anil D Patel; Isabella Irrcher; Michael Wall; Michael P McDermott
Journal:  J Neuroophthalmol       Date:  2016-03       Impact factor: 3.042
View more
  8 in total

1.  In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection.

Authors:  Nader S Abutaleb; Ahmed E M Elhassanny; Mohamed N Seleem
Journal:  Microb Pathog       Date:  2022-02-19       Impact factor: 3.738

2.  Mechanistic Studies and In Vivo Efficacy of an Oxadiazole-Containing Antibiotic.

Authors:  George A Naclerio; Nader S Abutaleb; Kenneth I Onyedibe; Caroline Karanja; Hassan E Eldesouky; Hsin-Wen Liang; Alexandra Dieterly; Uma K Aryal; Tiffany Lyle; Mohamed N Seleem; Herman O Sintim
Journal:  J Med Chem       Date:  2022-04-28       Impact factor: 8.039

3.  Anion inhibition studies of the α-carbonic anhydrases from Neisseria gonorrhoeae.

Authors:  Alessio Nocentini; Chad S Hewitt; Margaret D Mastrolorenzo; Daniel P Flaherty; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 4.  Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets.

Authors:  Daniel P Flaherty; Mohamed N Seleem; Claudiu T Supuran
Journal:  Future Med Chem       Date:  2021-08-12       Impact factor: 4.767

5.  Staphylococcus aureus Genomes Harbor Only MpsAB-Like Bicarbonate Transporter but Not Carbonic Anhydrase as Dissolved Inorganic Carbon Supply System.

Authors:  Sook-Ha Fan; Elisa Liberini; Friedrich Götz
Journal:  Microbiol Spectr       Date:  2021-11-03

6.  Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae.

Authors:  Nader S Abutaleb; Ahmed E M Elhassanny; Alessio Nocentini; Chad S Hewitt; Ahmed Elkashif; Bruce R Cooper; Claudiu T Supuran; Mohamed N Seleem; Daniel P Flaherty
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

7.  Inhibition studies of the protozoan α-carbonic anhydrase from Trypanosoma cruzi with phenols.

Authors:  Alessandro Bonardi; Seppo Parkkila; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

8.  Biological investigation of N-methyl thiosemicarbazones as antimicrobial agents and bacterial carbonic anhydrases inhibitors.

Authors:  Ilaria D'Agostino; Githa Elizabeth Mathew; Paola Angelini; Roberto Venanzoni; Giancarlo Angeles Flores; Andrea Angeli; Simone Carradori; Beatrice Marinacci; Luigi Menghini; Mohamed A Abdelgawad; Mohammed M Ghoneim; Bijo Mathew; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.